Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol
- 1 September 2011
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (9) , 3642-3652
Abstract
Apical membrane antigen 1 (AMA-1) is an invasion-relatedPlasmodiumantigen that is expressed during both intracellular and extracellular asexual stages of the parasite's life cycle, making it an ideal target for induction of humoral and cellular immune responses that can protect against malaria. We show here that when it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant human type 5 adenovirus (Ad), intense and long-lastingPlasmodium vivaxAMA-1-specific antibody responses (including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in immunized mice. Memory T cells displayed both central (CD44hiCD62Lhi) and effector (CD44hiCD62Llo) phenotypes, with the central memory phenotype prevailing (56% of AMA-1-specific proliferating cells). Considering the main traits of the memory immune responses induced against AMA-1, this particular sequence of immunogens (P followed by Ad), but no others (Ad/Ad, Ad/P, or P/P), displayed an optimal synergistic effect. These results give further support to the need for preclinical studies ofP. vivaxvaccine candidate AMA-1 administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.Keywords
This publication has 57 references indexed in Scilit:
- Adenovirus type-35 vectors block human CD4 + T-cell activation via CD46 ligationProceedings of the National Academy of Sciences, 2011
- The Th1 Immune Response toPlasmodium falciparumCircumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous InsertClinical and Vaccine Immunology, 2010
- Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 proteinMalaria Journal, 2010
- Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adultsVaccine, 2010
- A Trial of Combination Antimalarial Therapies in Children from Papua New GuineaNew England Journal of Medicine, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivaxAntimicrobial Agents and Chemotherapy, 2008
- Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccinesBlood, 2007
- Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus VectorsJournal of Virology, 2007
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007